ABSTRACT
C U R R EN T LY L IC EN S ED antiretroviral drugs target HIV-1 protease and reverse transcriptase (RT).
Resistance to antiretroviral drugs is frequently associated with selection of HIV-1 variants with mutations in these enzymes. To date, most studies of HIV-1 protease and RT have been performed for subtype (clade) B HIV-1, which is the most comm on subtype in the United States and Europe. In contrast, there are few studies characterizing these enzymes in non-B HIV-1, which accounts for the majority of HIV-1 infections worldwide. Characterization of these enzym es in non-B HIV-1 is becoming increasingly important, as the prevalence of non-B HIV-1 increases in countries where antiretroviral drugs are widely used, and the availability of antiretroviral drugs increases in developing countries.
Diverse HIV-1 subtypes are found in Uganda, where the prevalence of HIV-1 infection is high. While general use of antiretroviral drugs in Uganda is limited, Uganda has been the site of several clinical trials using antiretroviral drugs to treat and prevent HIV-1 infection. Most HIV-1 infections in Uganda are caused by subtype A and D HIV-1, 1,2 although infection with subtypes C 1,2 and G 3,4 has also been reported. These subtypes have been found in diverse regions throughout the world. In the United States, individuals have been identified with subtype A, C, and D HIV-1. [5] [6] [7] [8] [9] One study found subtype A HIV-1 in 2 of 22 individuals, 8 and another found 3 of 91 individuals to have non-B HIV-1, including 1 individual with subtype A who had no history of foreign travel or contact. 9 An important step in understanding the genetic correlates of drug resistance in non-B HIV-1 is to characterize the baseline sequences of HIV-1 protease and RT from individuals who have never received anti-retroviral therapy. In this sequence note we analyze HIV-1 protease and RT sequences from 27 antiretroviral drug-naive Ugandan adults.
Plasma samples used for analysis were obtained from asymptomatic volunteer blood donors at the Nakasero Blood Bank in Kampala, Uganda in 1993 and 1994. 1 Units from donors that were repeated reactive for HIV in donor-screening tests were not used for transfusion. Plasma samples from 27 of those units have been analyzed in this article. HIV-1 from the same samples was subtyped in a previous report by phylogenetic analysis of env gp41 and gag p24 sequences. 1 Most of the sam ples (24 of 27) had the sam e subtype in both the env and gag regions. Those included 15 subtype A, 2 subtype C, and 7 subtype D samples. Three samples contained recombinant HIV-1, one with subtype A in env and D in gag (A/D) and two with subtype D in env and subtype A in gag (D/A) ( Table 1) .
Analysis of HIV-1 protease and RT sequences was performed with the Perkin-Elmer/ Applied Biosystems (PE Biosystems) HIV genotyping system (HIV genotyping system Prt/59 RT; PE Biosystems, Foster City, CA). In this system , HIV-1 RNA is isolated from plasma and reverse transcribed with random hexamer prim ers and Moloney murine leukemia virus RT. An HIV-1 DNA fragment including the regions encoding protease (amino acids 1-99) and RT (amino acids 1-310) is amplified by polymerase chain reaction (PCR), using TaqGold in a single 40-cycle reaction. The amplified DNA is then purified and sequenced with six or seven primers and BigDye terminator reagents. Sequences are edited, aligned, translated into amino acids, and analyzed for the presence of amino acid polymorphism s. Controls to monitor for and prevent DNA contam ination in sample preparation and DNA amplification have been described previously. 10 Protease sequences from the 27 Ugandan isolates are shown in Fig. 1 . Phylogenetic methods were used to determine the subtype of each sample in the protease-coding region (Fig. 2) . Of the 27 samples, 17 had subtype A protease regions, and 10 had BECKER-PERGOLA ET AL. 808
FIG. 1.
Ugandan HIV-1 protease sequences. Ugandan plasma samples were analyzed with the PE Biosystem s HIV genotyping system as described. Protease sequences were aligned by the CLUSTAL method (MegA lign, DNASTAR, Lasergene). HIV-1 subtypes were defined for the protease region by using the corresponding nucleotide sequences (see subtype D protease regions. In 22 of 27 samples, the subtype of the gag and protease regions was the same (Table 1) . However, 5 of 27 samples had different gag and protease subtypes, suggesting recom bination between these regions. Interestingly, those included both samples that subtyped as C in the env and gag regions (225.745 and 108.448). One of those samples was a C/A recombinant and the other was a C/D recombinant. Comparison of the subtypes in all three regions (env, gag, and pro-UGANDAN HIV-1 PROTEASE AND REVERSE TRANSCRIPTASE 809
FIG. 2.
Phylogenetic analysis of HIV-1 protease sequences. Protease sequences (297 nucleotides) from the 27 Ugandan isolates were aligned with a set of 27 reference sequences from subtypes A-J recomm ended for HIV-1 subtyping. 11 Alignments were performed by the CLUSTAL method in the program Seqpup (Don Gilbert/ftp.bio.indiana.ed u). A neighbor-joining tree was constructed with 500 bootstrap replications of a Kimura two-param eter matrix to evaluate the robustness of the phylogenetic relationship between the sequences. The programs DNAdist and NEIGHBOR were used for this analysis. Bootstrap values were obtained from a consensus tree, using the program CONSENSE of the software package PHYLIP v3.572.0. The tree was rooted with the chimpanzee strain CPZGAB. Branch lengths are proportional to the amount of sequence divergence between taxa in the tree. The Ugandan isolates are indicated in boldface.
tease) revealed a high rate of recombination, involving 7 of 27 (26% ) of the sam ples; one sample (602.174) subtyped as D/A/D in env/gag/protease, suggesting that this variant was generated by multiple recombination events. Protease sequences shown in Fig. 1 were analyzed for the presence of amino acid polymorphism s at positions of previously characterized drug resistance mutations. 1 1 Polym orphisms were detected at nine of those positions (Table 2) . In subtype A, the polymorphisms M36I and H69K were present in all isolates. Comparison of the protease sequences in Fig. 1 also revealed polymorphism s at four positions that were different in subtype A versus D HIV-1. Most subtype A sequences had the amino acids D, K, K, and M at positions 35, 57, 69, and 89, whereas most subtype D sequences had the amino acids E, R, H, and L at those positions. For comparison, we analyzed the amino acid sequences at those positions in other HIV-1 subtypes (B, C, F, G, H, and J). 11 The DKKM pattern seen in Ugandan subtype A isolates was not seen in sequences from other subtypes. The ERHL pattern seen in Ugandan subtype D isolates was also prevalent among subtype B sequences, but was not seen in other subtypes. Rayfield et al. described a rapid method for identifying subtype A and D HIV-1 in Ugandan samples. 2 That method is based on nucleotide differences in the C2-V3 region of these subtypes. Nucleotide differences that encode amino acid polymorphism s in protease may also be exploited for rapid screening of Ugandan HIV-1 isolates to identify those that are likely to have subtype A or D protease-coding regions. Direct analysis of polymorphisms in protease may be desirable for studies of HIV-1 drug resistance, since our analysis reveals a high rate of intersubtype recombination between pol and other regions, such as env and gag.
RT sequences from the 27 Ugandan isolates were also analyzed (Fig. 3) . The corresponding nucleotide sequences were BECKER-PERGOLA ET AL. 810 a HIV-1 from 27 Ugandan plasma samples was amplified, sequenced, and subtyped by phylogenetic analysis. Subtyping of the env gp41 region and the gag p24 region was performed in a previous study. 1 Subtyping of the protease region is described in Fig. 2 . The subtype assignments for each region are shown. used for phylogenetic subtyping, using the reference sequences and methods described in Fig. 2 (data not shown) . The subtype assignments based on protease sequences and RT sequences were the same for 25 of 27 samples. For two of the sam ples (225.710 and 108.448), subtypes could not be definitively assigned on the basis of sequences from the RT region. The Ugandan RT sequences in Fig. 3 were examined for the presence of amino acid polymorphism s at positions in RT that are sites of previously characterized drug resistance mutations.
11 Amino acid polymorphism s were detected at five of those positions (Table 2) . Polymorphism s at the three positions (179, 211, and 214) were observed in multiple isolates. The polymorphism s V179I, R211S, and L214F were present in the majority of subtype A isolates. In contrast, most of the subtype D isolates had valine (V) at position 179 and lysine (K) at position 211; all the subtype D isolates had the L214F polymorphism. The significance of these polymorphism s in non-B HIV-1 is not known.
The low prevalence of prim ary drug resistance mutations in this population is consistent with the lack of widespread use of antiretroviral drugs in Uganda. It also demonstrates that primary drug resistance mutations identified in subtype B HIV-1 do not occur as common polymorphism s in HIV-1 from Uganda. It is interesting to note that many of the isolates contained polym orphism s at positions of previously characterized drug resistance mutations. Furthermore, many of the isolates contained amino acid mixtures at those positions (e.g., protease 60D/E, 63L/P, 63P/S, and 69H/Y and RT 179I/V, 211K/ R, and 214F/L). This suggests that HIV-1 variants with polym orphisms at those positions arise frequently in viral populations without drug selection.
It is not known whether drug resistance mutations characterized in subtype B HIV-1 have the same phenotypic effects in other HIV-1 subtypes. In theory, polymorphisms in HIV-1 protease and RT that vary among subtypes could influence the natural resistance of isolates to antiretroviral drugs, modulate the fitness of HIV-1 variants that acquire drug resistance mutations, or influence the probability that other mutations causing drug resistance would arise at those positions during drug selection. Studies comparing the genetic correlates of drug resistance in different HIV-1 subtypes are clearly needed to address these issues.
Genetic polymorphism s can complicate drug resistance analysis of HIV-1. Studies illustrate problem s that can arise by using genotypic assays based on hybridization. [12] [13] [14] The PE Biosystems HIV genotyping system used in this article was developed for analysis of subtype B HIV-1. In this system , sequence heterogeneity among HIV-1 subtypes can potentially interfere with reverse transcription, PCR amplification, or DNA sequencing, if primers fail to bind to the HIV-1 template. An abstract has described successful use of this system for analysis of cultured non-B HIV-1 reference isolates, using both kit and nonkit primers. 15 Here, we demonstrate successful use of this system for analysis of diverse HIV-1 subtypes in plasma, without the use of culture, and using only primers supplied by the manufacturer. Continued development and optimization of genotyping assays will be important for evaluation of HIV-1 protease and RT in drug-naive and drug-experienced patients with non-B HIV-1 infection. Such assays will play a key role in enhancing our understanding of drug resistance in non-subtype B HIV-1, and monitoring the emergence of drug-resistant HIV-1 worldwide.
